Shire PLC (SHPG) Shares Bought by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board raised its holdings in Shire PLC (NASDAQ:SHPG) by 218.7% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,432 shares of the biopharmaceutical company’s stock after buying an additional 60,000 shares during the period. Canada Pension Plan Investment Board’s holdings in Shire were worth $15,849,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Bank of Montreal Can acquired a new position in shares of Shire in the 2nd quarter valued at $3,607,000. Cornerstone Wealth Management LLC acquired a new position in shares of Shire in the 2nd quarter valued at $145,000. Eqis Capital Management Inc. acquired a new position in shares of Shire in the 2nd quarter valued at $541,000. First Trust Advisors LP increased its holdings in shares of Shire by 1.9% in the 2nd quarter. First Trust Advisors LP now owns 350,477 shares of the biopharmaceutical company’s stock valued at $59,161,000 after acquiring an additional 6,682 shares during the period. Finally, Sector Gamma AS increased its holdings in shares of Shire by 4.2% in the 2nd quarter. Sector Gamma AS now owns 171,825 shares of the biopharmaceutical company’s stock valued at $29,004,000 after acquiring an additional 6,850 shares during the period. Hedge funds and other institutional investors own 19.26% of the company’s stock.

Shares of SHPG opened at $175.58 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.51 and a current ratio of 0.92. The firm has a market capitalization of $53.37 billion, a price-to-earnings ratio of 11.59, a PEG ratio of 1.58 and a beta of 1.02. Shire PLC has a 1 year low of $123.73 and a 1 year high of $182.47.

Shire (NASDAQ:SHPG) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported $3.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.65 by ($0.01). The firm had revenue of $3.87 billion during the quarter. Shire had a net margin of 30.63% and a return on equity of 12.70%. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.81 earnings per share. As a group, equities research analysts expect that Shire PLC will post 15.08 EPS for the current year.

A number of brokerages have recently commented on SHPG. BidaskClub cut shares of Shire from a “buy” rating to a “hold” rating in a report on Friday. Zacks Investment Research reaffirmed a “hold” rating on shares of Shire in a report on Thursday, November 15th. ValuEngine raised shares of Shire from a “sell” rating to a “hold” rating in a report on Friday, August 24th. Berenberg Bank cut shares of Shire from a “buy” rating to a “hold” rating in a research note on Friday, September 7th. Finally, Evercore ISI cut shares of Shire from an “outperform” rating to a “market perform” rating and set a $196.00 price objective on the stock. in a research note on Tuesday, September 4th. Nine equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $201.11.

ILLEGAL ACTIVITY WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/12/03/shire-plc-shpg-shares-bought-by-canada-pension-plan-investment-board.html.

About Shire

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Read More: Why investors pay attention to retained earnings

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply